De-escalation of axillary surgery in clinically node positive (cN+) breast cancer patients is a topic of debate. The significant number of patients with axillary pathologic complete response (ax-pCR) resulting from increased use of neoadjuvant systemic therapy (NST) urges the need for a less invasive procedure to replace the conventional axillary lymph node dissection (ALND) in order to diminish unnecessary morbidity in patients with ax-pCR.^[@R1]--[@R3]^ Seeking for a less invasive procedure, both prevention of unnecessary morbidity and preservation of oncologic safety are of utmost importance.

Until recently, ALND was routinely performed after NST in cN+ patients, irrespective of axillary response to NST. Recent surveys among members of the American Society of Breast Surgeons as well as Dutch surgeons reported changes in axillary surgery in cN+ patients treated with NST.^[@R4],[@R5]^ The majority of specialists were willing to replace ALND by a less invasive staging procedure in patients with a favorable treatment response. A wide variety of less invasive staging procedures such as sentinel lymph node biopsy (SLNB), removal of a marked pathologically-proven positive lymph node (MARI and MARI-like procedures), or a combination of these two procedures (eg, targeted axillary dissection) are incorporated in clinical practice according to local preferences.^[@R6]--[@R9]^ These results denote the lack of consensus on the preferred procedure for axillary staging after NST in pretreatment cN+ patients. Up to now, it is not clear which procedure is optimal.

The aim of this review is to provide an overview of different less invasive procedures for axillary staging after NST in pretreatment cN+ patients, which are currently in use. By evaluating the accuracy of different less invasive axillary staging procedures, we aim to determine the optimal procedure for axillary staging after NST in cN+ breast cancer to safely replace ALND.

METHODS
=======

Criteria for Considering Studies for This Review
------------------------------------------------

This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for diagnostic test accuracy.^[@R10]^ A systematic literature search was performed by the first author (JM) for randomized controlled trials, cohort studies, and case-control studies testing less invasive axillary staging procedures after NST in cN+ breast cancer patients treated with NST. Studies were only included if nodal positivity was pathologically confirmed before starting with NST. Any study in which a less invasive axillary staging procedure was compared with the gold standard, that is, ALND, was included. In case completion ALND (cALND) was not performed routinely, studies were not considered for quantitative analysis. If relevant studies included both cN0 and cN+ patients, only the cN+ patients were considered for analysis. In case only part of the study population consisted of patients with pathologic confirmed nodal positivity, only the pathologically confirmed cN+ patients were considered for analysis. When it was not possible to discriminate between cN0 and cN+ patients or between pathologically confirmed and non-pathologically confirmed cN+ patients, studies were excluded. Reviews, case reports, conference abstracts, and editorials were excluded. In case of inclusion of the same study population in 2 or more papers, the most extensive paper was included. Studies reporting small study populations (10 patients or less) and studies in which nodal positivity was confirmed by SLNB before NST were excluded. The primary outcome was the overall ax-pCR rate and the accuracy of the studied less invasive axillary staging procedure. Studies were therefore excluded if reported data did not allow construction of a 2 x 2 contingency table with absolute numbers of true positive (TP), true negative (TN), false-positive (FP), and false-negative (FN) test results. FP is always 0, as the index test and reference test are considered the same in case of a positive index test result (ie, presence of residual axillary disease). The secondary outcome was the identification rate (IFR) of the studied less invasive axillary staging procedure.

Search Methods for Identification of Studies
--------------------------------------------

The following electronic databases were searched until April 20, 2018, with no restriction on language or date of publication: Medline (via PubMed) and EMBASE (via EMBASE.com).

A health sciences librarian was consulted to help develop a detailed search strategy. Details of the full search strategies in both databases are provided in Appendix 1. The reference lists of included studies and existing reviews were manually checked for additional relevant studies.

Selection of Studies and Quality Assessment
-------------------------------------------

Duplicate references were identified and removed with Endnote. Titles and abstracts of all remaining references were scanned independently by 2 authors (JS and TvN). Subsequently, these 2 authors independently assessed the full text papers of all potentially eligible studies. Disagreement was resolved by mutual consensus.

Eligible studies were assessed for quality using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS- 2) questionnaire.^[@R11]^ The QUADAS-2 was tailored to our analysis, as described in the guideline. Finally, all included studies were evaluated for quality by the 2 independent authors.

Data Extraction and Analysis
----------------------------

For each included study, the following parameters were extracted: first author, year of publication, type of hospital, study design, sample size, characteristics of trial participants (including primary tumor type, TNM-stage, type of evaluation of axillary involvement, and NST regimens), type of less invasive axillary staging procedure after NST and characteristics of the procedure, type of pathological assessment of lymph nodes (including use of immunohistochemistry (IHC), definition of ax-pCR, ax-pCR rate, accuracy, and IFR of the less invasive axillary staging procedure.

For each less invasive axillary staging procedure, the ax-pCR rate, IFR, false-negative rate (FNR), and negative predictive value (NPV) were calculated. Rate of ax-pCR was based on data of the contingency tables. The IFR was defined as the number of successful procedures divided by the total number of patients in whom the procedure was attempted. The FNR was defined as the number of FN divided by the total number of patients with presence of residual axillary disease \[FN / (FN + TP)\]. The NPV was defined as the number of TN divided by the total number of patients with a negative test result \[TN / (TN + FN)\]. As FP cannot occur, numbers of TP, TN, and FN were documented for each procedure and FP was always documented to be 0 (in case FP was reported to be \> 0 in the record, this number was added up to the TP number). Statistical analysis was performed with Stata/SE Statistical Software for Windows, version 14.2 (StataCorp LP, College Station, TX). To calculate pooled proportions for ax-pCR rate, IFR and FNR random-effects models for meta-analysis were used with 95% exact confidence intervals (CIs) with help of the metaprop command.^[@R12]^ All considered outcomes are presented in forest plots including pooled estimates. Chi-squared test was performed to test for statistical heterogeneity and was quantified by *I*^2^-index.^[@R13]^ As recommended in the Cochrane Handbook for Diagnostic Test Accuracy Reviews,^[@R14]^ reporting bias (eg, publication bias) was not assessed.

Subgroup analyses were performed to evaluate the impact of several factors on FNR. Factors that were considered relevant were number of examined lymph nodes, sampling method for SLNB, ycN status, definition of ax-pCR, and use of IHC in addition to standard H&E evaluation. Statistical significance was considered as *P* values (2-sided) ≤ 0.05.

RESULTS
=======

Study Selection
---------------

In total, 1920 records were identified through database searching and reference checking. After deduplication, 1132 records were screened, which resulted in the selection of 116 records for retrieval of full texts. Assessment of full text for eligibility yielded 27 records for qualitative synthesis; a total of 20 records were included in quantitative synthesis. See Fig. [1](#F1){ref-type="fig"} for a flow chart depicting the study selection process.

![Flow diagram depicting the study selection process.](ansu-269-432-g001){#F1}

Study Characteristics
---------------------

### Index Tests

Three different axillary staging procedures were identified: SLNB, excision of a pretreatment marked biopsy-proven positive lymph node (hereinafter all such procedures are referred to as ML), and a combination procedure involving both SLNB and ML. A total of 2217 patients were included (2002 for SLNB, 95 for ML, 120 for the combination procedure) in whom the axillary staging procedure was successful and followed by cALND. See Table [1](#T1){ref-type="table"} for general characteristics of all studies included for qualitative analysis.

###### 

General Characteristics of All Studies Included in Qualitative Analysis Sorted by Type of Procedure

  First Author     Year of Publication   Study Type   Index Test   Reference Test   Sample Size[^\*^](#TF1-1){ref-type="table-fn"}   cN-Stage   ycN-Stage                   Definition ax-pCR   IHC
  ---------------- --------------------- ------------ ------------ ---------------- ------------------------------------------------ ---------- --------------------------- ------------------- ------------------------
  Alvarado         2012                  R, S         SLNB         ALND             121                                              N1-N3      Any                         NR                  NR
  Boileau          2015                  P, M         SLNB         ALND             127                                              N1-2       Any                         ypN0/itc+           Yes, if H&E negative
  Boughey          2013                  P, M         SLNB         ALND             637                                              N1-2       Any                         ypN0/itc+           No
  Brown            2010                  R, S         SLNB         ALND             86                                               N1-3       Any                         ypN0/itc+           No
  Carrera          2016                  P, M         SLNB         ALND             48                                               N1-2       ycN0 (MRI +/- US)           NR                  Yes, always
  Enokido          2016                  P, M         SLNB         ALND             130                                              N1         ycN0 (imaging)              ypN0                NR
  Ge               2014                  P, S         SLNB         ALND             43                                               N1-3       Any                         NR                  Yes, but not routinely
  Kang             2011                  R, S         SLNB         ALND             58                                               N1-3       Any                         NR                  Yes, always
  Kuehn            2013                  P, M         SLNB         ALND             123                                              N1-2       ycN0 (PE +/-US)             ypN0/itc+           No
  Ozmen            2010                  R, S         SLNB         ALND             71                                               N1-2       ycN0 (PE and imaging)       ypN0                Yes, if H&E negative
  Park             2013                  R, S         SLNB         ALND             169                                              N1-3       Any                         ypN0/itc+           Yes, but not routinely
  Pinero-Madrona   2015                  P, M         SLNB         ALND             38                                               N1-3       Any                         NR                  NR
  Shen             2007                  P, S         SLNB         ALND             56                                               N1-3       Any                         NR                  No
  Thomas           2011                  P, S         SLNB         ALND             26                                               N+         ycN0 (PE)                   NR                  Yes, always
  Yagata           2013                  P, S         SLNB         ALND             81                                               N1-3       ycN0 (MRI; including rPR)   ypN0                Yes, if H&E negative
  Yu               2016                  R, S         SLNB         ALND             46                                               N+         ycN0 (PE)                   ypN0/itc+/mi+       Yes, always
  Zetterlund       2017                  P, M         SLNB         ALND             152                                              N1         Any                         ypN0                Yes, but not routinely
  Donker           2015                  P, S         ML           ALND             95                                               N1-3       Any                         ypN0                Yes, but not routinely
  Caudle           2016                  R, S         Combi        ALND             85                                               N1-3       Any                         ypN0                Yes, but not routinely
  Dashevsky        2017                  R, S         Combi        NA               21                                               N1-2       NR                          ypN0/itc+           No
  Diego            2016                  R, S         Combi        NA               29                                               N1         ycN0 (PE)                   ypN0                Yes, but not routinely
  Kim              2017                  P, S         Combi        NA               11                                               N1-2       Any                         ypN0/itc+           No
  Nguyen           2017                  R, S         Combi        NA               20                                               N1-3       NR                          NR                  NR
  Park             2017                  P, S         Combi        NA               20                                               N1-3       NR                          ypN0/itc+           Yes, but not routinely
  Plecha           2015                  R, S         Combi        NA               19                                               N1-3       NR                          NR                  NR
  Siso             2017                  P, S         Combi        ALND             35                                               N1-3       Any                         ypN0                Yes, always
  Taback           2018                  P, S         Combi        NA               19                                               N1-2       NR                          ypN0                NR

Combi indicates combination procedure; H&E, hematoxylin and eosin stain; IHC, immunohistochemistry; M, multicenter; NA, not applicable; NR, not reported; P, prospective; PE, psychical examination; R, retrospective; rPR, radiologic partial response; S, single-center.

^\*^Number of patients in whom the less invasive axillary staging procedure was successful and in whom this procedure was followed by cALND (if applicable).

### Reference Tests

In 20 studies, the axillary staging procedure was always followed by ALND as part of trial protocol. A total of 17 trials investigated accuracy of SLNB,^[@R15]--[@R31]^ 1 trial investigated ML,^[@R8]^ and 2 trials investigated a combination procedure.^[@R6],[@R32]^

Studies validating the combination procedure were scarce, yet several studies did report on cohorts of patients in whom a combination procedure was performed without routine cALND. Therefore, we decided to include these studies, 7 in total, in the qualitative analysis.^[@R7],[@R33]--[@R38]^ See Table [2](#T2){ref-type="table"} for detailed characteristics of these studies. In this table, we have included results of a study by our own research group (manuscript submitted). As cALND was not routinely performed in these studies, they were excluded from quantitative analysis.

###### 

Characteristics of Studies Involving the Combination Procedure Without Routine ALND

  Author                    Sample Size[^\*^](#TF2-1){ref-type="table-fn"}   Pre-NST Marking at Time of FNA/CNB   Pre-NST Marking After FNA/CNB   Post-NST Marking   Sampling SLNB    IFR^†^, %   ML is SLN, %   Confirmation Removal ML   Lymph Nodes[^‡^](#TF2-3){ref-type="table-fn"}, Median (Range)   ALND, %   Ax-pCR, %
  ------------------------- ------------------------------------------------ ------------------------------------ ------------------------------- ------------------ ---------------- ----------- -------------- ------------------------- --------------------------------------------------------------- --------- -----------
  Dashevsky                 21                                               Clip                                 NA                              Wire               Tc + blue        100.0       NR             XR                        NR                                                              0.0       33.3
  Diego                     29                                               Clip                                 NA                              Iodine seed        Tc + blue        100.0       91.0           XR                        4 (1--11)                                                       23.3      63.0
  Kim                       11                                               Clip                                 NA                              Wire               Tc + blue        100.0       NR             XR/palpation              NR                                                              45.5      36.4
  Nguyen                    20                                               NA                                   Clip                            Iodine seed        Tc and/or blue   100.0       NR             XR                        NR                                                              NR        NR
  Park                      20                                               NA                                   Charcoal                        NA                 Tc and/or blue   100.0       75.0           NA                        3 (1--12)                                                       60.0      50.0
  Plecha                    19                                               Clip                                 NA                              Wire               Tc ± blue        100.0       100.0          XR/PA                     5.7 (mean)                                                      NR        NR
  Simons (data submitted)   139                                              NA                                   Clip/Iodine Seed                Iodine seed/wire   Tc and/or blue   99.3        64.6           XR/PA                     2 (1--9)                                                        22.3      36.0
  Taback                    19                                               Clip (78.9%)                         Electromagnetic Reflector       NA                 Tc + blue        100.0       63.2           XR                        4 (2--10)                                                       31.6      31.6

NA indicates not applicable; NR, not reported (a pathologic assessment); Tc, technetium; XR, specimen radiography.

^\*^Patients who underwent successful ML in combination with SLNB.

^†^IFR refers to proportion of patients in whom at least 1 lymph node could be identified with the combination procedure.

^‡^Number of lymph nodes of the combination procedure and not the number of lymph nodes of either ML or either SLNB.

Risk of Bias and Applicability
------------------------------

Figure [2](#F2){ref-type="fig"} shows the methodological quality of all included studies. In general, studies included in the quantitative analysis showed a lower risk of bias than studies included only in the qualitative analysis.

![Assessment of risk of bias.](ansu-269-432-g002){#F2}

Results of Individual Studies Included in Quantitative Analysis
---------------------------------------------------------------

Pooled Prevalence of ax-pCR

The overall prevalence of ax-pCR in all 20 included studies was 37% (see Appendix 2). The *I*^2^-statistic was 57.08% (*P* \< 0.01). Test for heterogeneity between subgroups based on staging procedure was not significant, supporting the pooling of all studies in 1 overall rate.

### SLNB

The IFR of SLNB was available for 16 of 17 studies. The overall IFR was 89% in a pooled sample of 2154 patients (see Appendix 3). For all studies, data to calculate FNR and NPV were available for a total of 2002 patients. An overall FNR of 17% was found (see Fig. [3](#F3){ref-type="fig"}) and NPV ranged from 57% to 86% (see Table [3](#T3){ref-type="table"} SLNB). The *I*^2^ statistic revealed values of variation due to heterogeneity of 68.3% for IFR and 38.7% for FNR (*P* \< 0.01 and *P* = 0.05, respectively).

![Forest plot for the FNR of SLNB.](ansu-269-432-g003){#F3}

###### 

Overview and Diagnostic Accuracy Sorted by Type of Procedure

  SLNB                                                                                                         
  ---------------- ------ --------------------- -------------------- ------ ----- --- ---- ----- ------------- -------------
  Alvarado         92.7   Tc and/or blue        2 (1--7)             35     57    0   15   39    21 (12--32)   72 (58--84)
  Boileau          87.6   Tc and/or blue        2.7 (mean)           35     76    0   7    44    8 (3--17)     86 (74--94)
  Boughey          92.7   Tc and/or blue        NR                   40.0   326   0   56   255   15 (11--19)   82 (77--86)
  Brown            NR     Tc and/or blue        2 (1--10)            30.2   47    0   13   26    22 (12--34)   67 (50--81)
  Carrera          90.5   Single radioactive    2.2 (mean) (1--6)    35.4   28    0   3    17    10 (2--26)    85 (62--97)
  Enokido          90.9   Tc and/or blue        1.6 (mean)           52     49    0   13   68    21 (12--33)   84 (74--91)
  Ge               84.3   Tc and/or blue        2.4 (1--7)           27.9   25    0   6    12    19 (7--37)    67 (41--87)
  Kang             87.9   Tc and/or blue        2.8 (mean) (1--8)    28.8   34    0   7    17    17 (7--32)    71 (49--87)
  Kuehn            82.6   Tc ± blue             NR                   48.8   51    0   12   60    19 (10--31)   83 (73--91)
  Ozmen            92.2   Tc + blue             2.1 (1--5)           28     44    0   7    20    14 (6--26)    74 (54--89)
  Park             94.9   Single, radioactive   2,1 (mean) (1--12)   40.8   78    0   22   69    22 (14--31)   76 (66--84)
  Pinero-Madrona   84.0   Tc ± blue             NR                   34.2   15    0   10   13    40 (21--61)   57 (34--77)
  Shen             92.8   Tc and/or blue        2 (1--10)            28.6   30    0   10   16    25 (13--41)   62 (41--80)
  Thomas           86.7   Single blue           1,57 (mean) (1--4)   31     15    0   3    8     17 (4--41)    73 (39--94)
  Yagata           85.3   Tc + blue             2 (1--7)             37     43    0   8    30    16 (7--29)    79 (63--90)
  Yu               95.8   Single: Blue          1,48 (mean) (1--4)   52.2   14    0   8    24    36 (17--59)   75 (57--89)
  Zetterlund       77.9   Tc and/or Blue        2 (1--5)             39.5   79    0   13   60    14 (8--23)    82 (71--90)

  ML                                                                        
  -------- ---- ------------- ---- --- ---- ---- --- --- ---- ------------- -------------
  Donker   97   Iodine seed   NA   1   26   65   0   5   25   7 (2 -- 16)   83 (65--94)

  Combination                                                                                                                                  
  ------------- ------ ---------------- ------ --------------------------------------- ---------- ------ ------- ---- --- --- ---- ----------- ------------
  Caudle        100%   Tc and/or blue   Clip   Iodine seed                             NR         41     77^†^   49   0   1   35   2 (0--11)   97 (85--1)
  Siso          NR     Tc and/or blue   Clip   NA[^\*^](#TF3-1){ref-type="table-fn"}   3 median   31.7   77      23   0   1   11   4 (0--21)   92 (62--1)

NA indicates not applicable; NR, not reported; Tc, technetium.

^\*^Ax-pCR rate based on data of 2 × 2 contingency tables.

^†^Rate is based on 134 patients with a clipped node that underwent SLNB (it was documented if the clipped node was identified as an SLN). Eighty-five patients actually underwent TAD followed by cALND.

Ten studies documented the definition of ax-pCR: overall FNR was 16% when ax-pCR was defined as ypN0 and 17% when ax-PCR was defined as ypN0/itc+ (*P* = 0.61, 1 study defined ax-pCR as ypN0/itc+/mi+). FNR was reported for single versus dual-tracer sampling separately in 5 studies and another 6 studies used either single-tracer or dual-tracer sampling in 100% of patients. Pooled FNR was 13% for dual-tracer sampling and 16% for single-tracer sampling (*P* = 0.53). A total of 14 studies reported on the use of IHC: overall FNR was 15% when IHC was used (either always or in selected patients) versus 17% when IHC was not used (*P* = 0.47). In 6 studies, FNR was reported separately in relation to the number of SLN(s): all 6 studies reported FNR for excision of 3 or more SLNs (NB: in 1 study, this was 2 or more SLNs) and 5 of 6 studies also reported FNR for excision of \<3 SLNs. Overall FNR was 8% with removal of at least 3 SLNs and 22% with removal of \< 3 SLN(s) (*P* \< 0.0001). In 7 studies, only cN+ patients with ycN0 status were included. In addition to these studies, another 4 studies reported on FNR separately for patients with any ycN status versus ycN0 status. Overall FNR was 14% when only patients with ycN0 status were taken into account versus 18% when patients irrespective of ycN status were taken into account (*P* = 0.14).

### ML

One study reported on a ML procedure: this study involved the validation of the MARI procedure (marking axillary lymph nodes with radioactive iodine seeds) in 95 patients. In this study, the pathologically proven positive lymph node was marked with an I-125 seed pre-NST. After completion of NST, at the time of surgery, the lymph node with the Iodine seed was removed. The IFR was 97%, the FNR 7%, and the NPV 83.3%. See Table [3](#T3){ref-type="table"} (ML) for characteristics of this procedure.

### Combination Procedure

Two studies investigated a combination procedure: one involved clipping of the positive lymph node pre-NST later followed by I-125 seed localization of the clipped node post-NST in combination with SLNB and one involved clipping of the positive lymph node pre-NST followed by US-guided excision of the clipped-node in combination with SLNB. Table [3](#T3){ref-type="table"} (Combination) shows values for FNR and NPV for the 2 combination procedures. As only 2 studies were available for analysis, pooling of proportions was not performed. The studies appeared clinically similar, as they targeted the same population in terms of inclusion criteria, definition of ax-pCR, and use of IHC.

DISCUSSION
==========

In this systematic review, the accuracy of 3 different procedures for axillary staging after NST in cN+ patients was evaluated. This is the first review up to now that compared all these different less invasive staging procedures with the gold standard ALND. The goal was to provide an overview of currently available procedures in order to guide decision making regarding replacing ALND in selected cN+ patients.

The SLNB for axillary staging after NST in cN+ patients has been extensively studied over the past years. The SLNB procedure is widely accepted as axillary staging procedure in cN0 patients. Even when performed after NST, the accuracy of SLNB for cN0 patients is accepted.^[@R39]^ SLNB for axillary staging after NST in pre-treatment cN+ patients, however, is associated with unacceptably high rates of FNR. In 2015, the accuracy of SLNB in cN+ patients after NST was evaluated in a systematic review that included 8 studies with pathologically proven cN+ patients.^[@R40]^ That review reported an overall FNR of 15% and the NPV of SLNB did not exceed 86%.^[@R40]^ In the current meta-analysis, a total of 17 studies with 2002 patients (the 8 studies of the previous review were also included) were analyzed. The overall FNR is 17% and the NPV still does not exceed 86%: in case SLNB predicts ax-PCR, residual axillary disease is actually missed in at least 1 in 6 patients. The overall IFR is 89%. Previous studies reported multiple factors that may improve IFR and accuracy of SLNB, for example, using dual-tracer sampling technique, evaluating the SLNs with IHC in addition to standard H&E evaluation and removing 3 or more SLNs. As IHC and single- versus dual-tracer sampling was not used consistently within and between studies, it is not possible to draw definite conclusions from this review on whether/or not specific sampling and pathologic evaluation methods should be promoted. Our results did show that FNR was favorable (yet not statistically significant) for both dual-tracer sampling and pathologic evaluation with IHC. FNR was also favorable for patients with ycN0 status based on physical examination and/or imaging compared with any ycN status (FNR of 14% vs 18%, *P* = 0.14). Regarding the number of SLNs, removing ≥ 3 lymph nodes was associated with a significantly better FNR in our meta-analysis (8% vs 22%, *P* \< 0.0001). However, removing ≥ 3 SLNs is not achievable in a significant number of patients^[@R17]^ and whether this will be achieved is unpredictable preoperatively. This renders SLNB impractical, as random node-picking should be discouraged. Currently recruiting studies as Alliance 11202 and NSABP-51/RTOG 1304 will determine whether the SLNB, despite its rather poor overall accuracy and shortcomings, can have a place in axillary staging after NST in cN+ patients.^[@R41],[@R42]^

The MARI procedure was the first ML procedure to be proposed as an alternative to SLNB for axillary staging after NST in cN+ patients.^[@R8]^ By marking the pathologically proven positive lymph node before start of NST, it was expected to enable accurate assessment of treatment response after completion of NST. The MARI procedure was validated in 1 single-center trial with 95 patients. This study reported an improved FNR (7%), but the NPV of 83.3% was less favorable, that is, in 1 of 6 patients with a negative MARI, axillary residual disease is left behind. Therefore, equally to SLNB, MARI as a stand-alone procedure is insufficiently accurate to safely replace ALND. Despite the shortcomings of MARI (potential of missing residual axillary disease and limited evidence by 1 single---dedicated breast cancer---center trial to support this procedure), it is already implemented in clinical practice. A recent publication suggests combining information on axillary burden on pre-NST PET-CT (ie, number of suspicious lymph nodes: \<4 vs ≥ 4) with MARI outcome^[@R9]^ to determine adjuvant axillary treatment: no further axillary treatment, axillary radiotherapy, or cALND with axillary radiotherapy. Results of 1 prospective implementation study showed that this treatment strategy indeed results in a major reduction of ALND.^[@R43]^ Data of longer follow-up have to determine whether implementation of this protocol is untimely and whether it does not only reduce morbidity but also preserves oncologic safety in terms of disease-free and overall survival. Prospective trials with sufficient follow-up are therefore urgently needed.

In the Z1071 trial, a clip was placed in the positive lymph node before NST in a subset of patients.^[@R44]^ The trial protocol did not require surgeons to selectively target and remove the clipped node at time of surgery, but did encourage surgeons and pathologists to document whether the clipped node was located in the SLNB or ALND specimen. In 141 of 170 patients with a clipped node, the location of the clipped node was documented: 75.9% in the SLNB specimen and 24.1% in the ALND specimen. This suggested that removing the clipped node together with SLN(s) at time of surgery may improve accuracy of SLNB and may possibly overcome shortcomings associated with SLNB or MARI if used as stand-alone procedures. Up to now, only 2 trials evaluated accuracy of such a combination procedure and were included in our meta-analysis.^[@R6],[@R32]^ This procedure is associated with excellent IFRs. Caudle et al^[@R6]^ confirmed that the clipped node does not necessarily have to be a SLN, as this was the case in only 77%. Furthermore, FNR is low (2% to 4%) and NPV is high (92% to 97%). These results are promising: when ax-pCR is predicted, residual axillary disease is missed in 1 in 12 to 33 patients. The evidence for this procedure is yet limited with only 2 trials available (1 retrospective and 1 prospective study), involving small sample sizes and single-center study designs. The ongoing Dutch RISAS trial (NCT02800317 at [https://clinicaltrials.gov](https://clinicaltrials.gov/)) will prove whether the promising results of a combination procedure can be confirmed in a large, prospective, multicenter trial.^[@R45]^

Although evidence to support replacing ALND by less invasive procedures is limited, several reports have been recently published on implementation of such procedures, especially procedures involving excision of the ML and SLNs. A variety of methods are used to target the pathologically proven positive lymph node: marking with a clip pre-NST followed by placing an iodine seed or wire in the clipped node post-NST^[@R7],[@R33]--[@R35],[@R37]^ and primary marking with an iodine seed, clip, charcoal, or electromagnetic reflector.^[@R36],[@R38]^ Also, the time of marking the lymph node pre-NST differs: either immediately at time of FNAC/CNB,^[@R7],[@R33],[@R34],[@R37]^ at a second appointment once metastatic burden of the punctured lymph node is confirmed by the pathologist^[@R35],[@R36]^ or even at both occasions.^[@R38]^ Currently, further research has to define which combination procedure is most accurate, patient-friendly, and cost-effective. Identification of the ML at time of surgery is highly feasible, provided that clipping (with/without secondary localization of the clip) of the node was successful. Success rates of this part of the procedure are often not sufficiently reported and may be improved to further optimize combination procedures.

The abovementioned 3 different staging procedures intend to offer a less invasive strategy compared with the conventional ALND, yet ≥ 10 lymph nodes are removed in some patients with SLNB and combination procedures. It is important to realize that these procedures serve as a staging procedure to identify ax-pCR and not as a managing procedure to remove all residual diseases. Hence, it should be the primary goal to remove as few lymph nodes as possible. In this way, patients with ax-pCR can truly benefit from less invasive staging procedures. At the same time, when these procedures identify axillary residual disease, adjuvant axillary treatment plans should consist of cALND. Results of the Alliance 11202 and NSABP-51/RTOG 1304 trials have to be awaited to determine whether cALND may be replaced by axillary radiation therapy.^[@R41],[@R42]^

As this review is limited by the heterogeneity of included studies, results of the review should be interpreted with caution. The random effects model that was used for statistical analysis takes in account that, although similar interventions were studied, different populations were included. Factors such as definition of ax-PCR, sampling method for SLNB, and use of IHC for pathologic assessment of lymph nodes may all impact accuracy of the studied intervention. These factors differed widely among included studies and further research is necessary to determine, among others, what should be the preferred definition of ax-pCR. The prognostic impact of residual ITCs and micrometastasis may be different for patients treated in the neoadjuvant compared with adjuvant setting, as they might be therapy-resistant. A retrospective study of cN+ patients treated with NAC and always followed by ALND suggested that patients with residual ITCs and micrometastases carry a similar prognosis as patients with ypN0.^[@R46]^ These results have yet to be confirmed in trials where patients with ypN0 and ITCs or micrometastasis did not undergo ALND. In addition, the value of IHC has not yet been thoroughly studied, as most studies that used IHC in addition to standard H&E evaluation, did so randomly, and not in a routine matter. Contrary to improving accuracy of detecting residual axillary disease, a potential undesired result of IHC may be detection of residual disease that would have otherwise been left undetected (of which implications on prognosis and need for adjuvant treatment are unknown). The question whether IHC may not only result in improved accuracy but may also result in overtreatment is yet left unanswered.

In this review, we only included patients in whom cN+ status was pathologically proven before NST. This is particularly important to determine true accuracy of the different staging procedures. When patients who are expected to be cN+ based on physical examination or imaging only, the number of true negatives rises and the chance to have false negatives decreases. This may result in a false impression of improved rates of FNR and NPV.

In conclusion, the SLNB as well as ML procedures seem insufficiently accurate as stand-alone procedures for axillary staging after NST in cN+ patients. Accuracy of these procedures may improve by taken in account axillary burden on pre-NST and/or post-NST imaging. A combination procedure involving excision of the ML and SLNs appears most accurate for axillary staging and has the lowest risk of missing axillary residual disease when ax-pCR is predicted. More evidence from prospective multicenter trials is needed to confirm this.
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Appendix 1
==========

**PubMed search strategy**

("Breast Neoplasms"\[Mesh\] OR ((carcinoma OR carcinomas OR tumor OR tumours OR tumour OR tumours OR neoplasm OR neoplasms OR malignancy OR adenocarcinoma OR cancer) AND (breast OR mamma))) AND ("Sentinel Lymph Node Biopsy"\[Mesh\] OR sentinel lymph node biopsy OR slnb OR (MARI\[tiab\]) OR (Axilla∗ AND staging\[tiab\]) OR targeted axillary dissection) AND (sensitivity OR specificity OR "Sensitivity and Specificity"\[Mesh\] OR "Predictive Value of Tests"\[Mesh\] OR negative predictive value OR positive predictive value OR likelihood ratio OR diagnosis OR "false-negative" OR "false-positive") AND ("Lymph Nodes"\[Mesh\] OR "Lymphatic Vessels"\[Mesh\] OR "Lymphatic Metastasis"\[Mesh\] OR "Lymphatic System"\[Mesh\] OR "Axilla"\[Mesh\] OR axilla∗) AND (("Neoadjuvant Therapy"\[Mesh\] OR neoadjuvant OR preoperative∗ OR primary) AND ("Antineoplastic Agents"\[Mesh\] OR chemotherapy OR immunotherapy OR systemic therapy))

**EMBASE search strategy∗**

∗Search results were restricted to articles, reviews, articles in press, conference paper, conference review

((breast OR mamma) AND (cancer OR carcinoma OR neoplasm OR malignancy OR adenocarcinoma OR 'breast cancer'/exp OR tumor OR carcinomas OR tumors OR tumour OR tumours)) AND ((\'sentinel lymph node biops∗' OR slnb OR \'sentinel node∗' OR \'sentinel lymph node biopsy'/exp OR 'mari':ab,ti OR (axilla∗ AND staging) OR 'targeted axillary dissection')) AND (sensitivity OR specificity OR 'predictive value' OR 'likelihood ratio' OR ppv OR npv OR diagnosis OR 'false negative' OR 'false positive') AND ((axilla∗ OR lymph∗) AND (node∗ OR metastasis)) AND ((neoadjuvant OR primary OR preoperative∗) AND (therapy OR immunotherapy OR chemotherapy OR systemic))

Appendix 2. Forest plot of the ax-pCR rate.
===========================================
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ES effect size. The pooled ax-pCR is 37% (33% to 40%).

Appendix 3. Forest plot for the identification rate of SLNB.
============================================================
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ES. effect size. The pooled identification rate of SLNB is 89% (87% to 92%).
